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Over the last decade, polymer micelles and nanoparticles attracted an increasing interest 
in drug research because they can be used as efficient drug delivery systems1. Nanoparticles are 
submicron-sized polymeric colloidal particles with a therapeutic agent of interest encapsulated 
within their polymeric matrix2. The addition of an amphiphilic block copolymer made up of 
poly(ethylene oxide) and an aliphatic polyester, such as poly(ε-caprolactone) (PCL) or 
polylactide (PLA), to the formulation permits to take advantage of the protein repellent properties 
of PEO to increase the time live of the nanoparticles in the vascular residence. 
The use of polymeric nanoparticles for the delivery of complex antigens, the combination 
of antigens, and genetic vaccines makes them one of the most promising strategies for oral 
vaccination3. Polymeric carriers protect antigens against degradation and inactivation in the harsh 
gastro-intestinal environment and have the ability to enhance their transmucosal transport. When 
these copolymers have a targeting agent, the biodistribution of polymeric micelles can be 
modulated and can induce specific cellular uptake by receptor-mediated endocytosis. 
The presence of RGD allows the targeting of β1 integrins at the apical surface of human 
M cells and the enhancement of an immune response after oral immunization. Is it possible that 
RGD peptide partial degraded during its transport in the gastrointestinal tract.  
  To check the hypothesis that a non-peptidic ligand could exhibit a higher stability in the 
gastrointestinal tract, new non-peptidic ligands targeting intestinal M cells or APCs for oral 
immunisation were grafted onto the PEG chain of PCL-b-PEG copolymer and incorporated in 
PLGA-based nanoparticles. The presence of GRGDS and RGDp in the formulation significantly 
increased the transport of nanoparticles across an in vitro model of human M cells compared to 
enterocytes, due to interactions between those ligands and the β1 integrins detected at the M cell 
apical surface.  In vivo, an immune response was induced after intragastric and intraduodenal 
administration of ovalbumin loaded-nanoparticles. Targeted formulations were also able to 
induce a cellular immune response. In conclusion, the in vitro transport of nanoparticles and the 
immune response were positively influenced by the presence of ligands at the surface of 
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